Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Duong, Connie P M ^a   Westwood, Jennifer A ^a   Yong, Carmen S M ^a   Murphy, Amanda ^a   Devaud, Christel ^a   John, Liza B ^a   Darcy, Phillip K ^a,b   Kershaw, Michael H ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL ENGINEERING; CONTROLLED STUDY; DNA LIBRARY; GENE IDENTIFICATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOLECULAR CLONING; MOLECULAR SIZE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIGENS, CD27; CELL ENGINEERING; CELL LINE, TUMOR; GENE LIBRARY; GENES, ERBB-2; GENETIC VECTORS; HUMANS; MICE; RECEPTORS, ANTIGEN; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 84877141205     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063037     Document Type: Article

References (26)

1. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121: 1822-1826.
2. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, et al. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106: 3360-3365.
3. Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, et al. (2002) Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 25: 139-151.
4. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE, (2010) Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 10: 77-90.
5. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M, (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20: 70-75.
6. Lo AS, Ma Q, Liu DL, Junghans RP, (2010) Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 16: 2769-2780.
7. Marzo AL, Lake RA, Robinson BW, Scott B, (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59: 1071-1079.
8. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW, (1991) Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173: 1007-1015.
9. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A, (1998) Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395: 82-86.
10. Padhan K, Varma R, (2010) Immunological synapse: a multi-protein signalling cellular apparatus for controlling gene expression. Immunology 129: 322-328.
11. Eshhar Z, Waks T, Gross G, Schindler DG, (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90: 720-724.
12. Morgan RA, Johnson LA, Davis J, Zheng Z, Woolard K, et al. (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther.
13. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, et al. (2012) A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119: 5697-5705.
14. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, et al. (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155-3163.
15. Lam JS, Reeves ME, Cowherd R, Rosenberg SA, Hwu P, (1996) Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. Hum Gene Ther 7: 1415-1422.
16. Alonso-Camino V, Sanchez-Martin D, Compte M, Sanz L, Alvarez-Vallina L, (2009) Lymphocyte display: a novel antibody selection platform based on T cell activation. PLoS One 4: e7174.
17. Ma Q, DeMarte L, Wang Y, Stanners CP, Junghans RP, (2004) Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther 11: 297-306.
18. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z, (2005) Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105: 3087-3093.
19. Wilkie S, Picco G, Foster J, Davies DM, Julien S, et al. (2008) Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 180: 4901-4909.
20. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M, (2010) Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 18: 413-420.
21. Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, et al. (2004) A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 11: 371-379.
22. Song DG, Ye Q, Poussin M, Harms GM, Figini M, et al. (2012) CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119: 696-706.
23. Marin V, Kakuda H, Dander E, Imai C, Campana D, et al. (2007) Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol 35: 1388-1397.
24. Wu J, Song Y, Bakker AB, Bauer S, Spies T, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
25. Shiloni E, Karp SE, Custer MC, Shilyansky J, Restifo NP, et al. (1993) Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunol Immunother 37: 286-292.
26. Bestwick RK, Kozak SL, Kabat D, (1988) Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. Proc Natl Acad Sci U S A 85: 5404-5408.